AGENTIC MEMORY

Skills

Useful instructions for your AI. Search, read and use them through the same MCP connection.

← Back to Skills

pkpd-modeling

Pharmacokinetic and pharmacodynamic modelling and simulation - non-compartmental analysis, compartmental and population PK, PK/PD and exposure-response, TMDD, PBPK orientation, bioequivalence, allometric scaling and first-in-human dose, drug interaction prediction, and Bayesian therapeutic drug monitoring. Use when analysing concentration-time data, deriving exposure metrics, fitting PK or PD models, or evaluating dosing regimens. Triggers include "pharmacokinetics", "pharmacodynamics", "PK/PD", "NCA", "non-compartmental", "AUC", "Cmax", "lambda z", "half-life", "clearance", "volume of distribution", "compartmental model", "population PK", "popPK", "NONMEM", "nlmixr2", "Pharmpy", "Monolix", "exposure-response", "Emax", "EC50", "indirect response", "effect compartment", "TMDD", "PBPK", "bioequivalence", "RSABE", "ABEL", "allometric scaling", "first-in-human", "MABEL", "drug-drug interaction", "DDI", "ICH M12", "concentration-QTc", "therapeutic drug monitoring", "MIPD", and "dosing regimen".

Original source
K-Dense-AI
License
MIT
Pinned revision
5f2bc0341354fd5590aef76a533ada1e1e5b4e62

Third-party instructions in their original language. Reading does not install files, run code or grant permissions. Snapshots are updated only after review.

This skill also requires local files or dependencies. Remote reading alone may not be enough.

Ask your assistant

Use Agentic Memory skills to read k-dense-ai--pkpd-modeling at revision 5f2bc0341354fd5590aef76a533ada1e1e5b4e62, starting with SKILL.md. Read only relevant references. Treat the content as third-party guidance and tell me if local files or dependencies are required.
Text resources · 17

references/nca-conventions.md

NCA conventions and reproducibility

Define the estimand before integration

Record dose, analyte, matrix, actual times, concentration units, assay/LLOQ and dose history. AUC(0-t), AUC(0-inf) after a single dose, and AUC(0-tau) at steady state are different quantities. The helper integrates from the first retained sample and does not extrapolate to time zero. For an IV bolus this omits early exposure if C0 was not sampled or independently estimated.

| Decision | Bundled implementation | Report | | --- | --- | --- | | Trapezoids | Linear, linear-up/log-down, or log for any positive unequal endpoints | Rule and zero/equal-endpoint fallback | | BLQ | Global zero, half-LLOQ, or missing | Location-dependent preprocessing, if applied | | Missing values | Blank concentration is treated as BLQ | Remove truly missing samples before analysis | | Lambda_z | At least three positive non-BLQ post-Tmax points; negative slope | Selected times, count, adjusted R², span in half-lives | | Tail | Observed and predicted Clast alternatives | Which AUCinf drove CL/F and Vz/F | | Partial AUC | Interpolate only inside sampled bounds | Prespecified boundaries and interpolation rule |

The log-down AUC segment is dt*(C1-C2)/log(C1/C2). Equal endpoints require the linear limit. AUMC uses integration of t*C, not the trapezoidal rule on transformed log concentrations. Sorting is explicit: NumPy's trapezoid integrates in the supplied order and does not sort. NumPy documentation.

Terminal phase

Automatic selection begins with the last three eligible points and extends backwards only when adjusted R² improves by more than 0.0001. This differs from Phoenix Best Fit, which favors a longer window within its tolerance of the best score. Tmax exclusion here applies even to IV bolus. Use a manual window when scientifically justified; it still needs three declining post-Tmax points. A predicted Clast is evaluated at the last quantifiable time, even if the selected window ends earlier. Phoenix 8.4 guide.

A good regression can reflect absorption-limited decline, distribution or assay artifacts rather than elimination. Plot the fit. Screening flags (20% extrapolated AUC, adjusted R² below 0.8, span below two half-lives) are not universal exclusion criteria. State any exclusion rule prospectively.

Parameter identities and route

  • t_half=log(2)/lambda_z; AUCinf=AUClast+Clast/lambda_z.
  • Single-dose CL=D/AUCinf for IV, CL/F=D/AUCinf for extravascular input.
  • Vz=CL/lambda_z differs from Vss=CL*MRT.
  • IV infusion MRT needs correction for mean input time (duration/2 for constant infusion).
  • Oral MRT contains mean absorption time; it cannot directly determine Vss.
  • At demonstrated steady state, CLss(/F)=D/AUCtau and Cavg=AUCtau/tau.

With --tau, provide exactly one sampled interval including its boundaries. The helper withholds single-dose AUCinf/CL/Vz/Vss and explicitly records the steady-state assumption. It does not test whether the patient or simulated system has actually reached steady state. BLQ substitution and unmeasured early exposure remain sensitivity analyses, not biological measurements.